An unusual case of haemolytic uraemic syndrome following endoscopic retro- grade cholangiopancreatography rapidly improved with eculizumab
Journal | Volume 79 - 2016 |
Issue | Fasc.2 - Case reports |
Author(s) | Olivier Taton, Myriam Delhaye, Patrick Stordeur, Timothy Goodship, Alain Le Moine, Annick Massart |
Full article |
VIEW FREE PDF |
(1) Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, (2) Immunochemistry-Autoimmunity Laboratory, Immunobiology Clinic, Erasme Hospital, Brussels, Belgium ; (3) Institute of Genetic Medicine, Newcastle University, Central Parkway, United Kingdom ; (4) Department of Nephrology, Dialysis and Transplantation, Erasme Hospital, Brussels, Belgium. |
Atypical haemolytic uraemic syndrome (aHUS) is a rare but life- threatening complement system-related disorder, characterized by renal failure, non-immune haemolytic anaemia and thrombo- cytopenia. We report on a young woman who developed a pancre- atitis-induced aHUS following a routine procedure of endoscopic retrograde cholangiopancreatography. The patient was succes- sively treated by 2 plasma exchanges with fresh frozen plasma and eculizumab, a monoclonal antibody designed to block terminal complement activation. The last treatment resulted in the immedi- ate improvement of haemolytic parameters and to the definitive suspension of plasma exchanges. This is likely the first description of the use of a complement inhibitor to treat post-pancreatitis aHUS. We discussed treatment options and concluded that eculi- zumab could be a beneficial alternative to plasma exchanges in the management of such complications. (Acta gastroenterol. belg., 2016, 79, 257-261). |
© Acta Gastro-Enterologica Belgica. PMID 27382949 |